Richard A. Heyman, Director at Enliven Therapeutics, Inc. (ELVN), sold 1,270 shares at $27.67 ($35K) on 2024-10-15, disclosed to the SEC on 2024-10-17.
Scheduled sale ($35k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ELVN | SELL | 2026-02-19 | $32K | — | Filing → |
| ELVN | SELL | 2026-01-22 | $33K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |